
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Governmental regulations, insurance companies and their requirements, and other hassles have made your jobs more difficult in 2016, according to our 4th annual Issues and Attitudes survey.
]






